{
    "nct_id": "NCT05157971",
    "official_title": "A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia",
    "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* Age between 18 and 54 years\n* Eastern Cooperative Oncology Group (ECOG) =< 2\n* Histologically confirmed B-cell ALL according to World Health Organization criteria\n\n  * Note: Lymphoblastic leukemia is included as long as there is bone marrow involvement\n* Newly diagnosed disease with >= 5% blasts in the marrow\n* White blood cell count less than 25 x 10^9/L prior to initiation of venetoclax. Cytoreduction with hydroxyurea or steroid or a single dose of intrathecal chemotherapy prior to treatment may be required (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Total bilirubin =< 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease or underlying leukemia, =< 3 X ULN) (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Aspartate aminotransferase (AST) =< 2.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * Unless it is related to underlying leukemia\n* Alanine aminotransferase (ALT) =< 2.5 x ULN (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * Unless it is related to underlying leukemia\n* Creatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (performed within 14 days prior to day 1 of protocol therapy unless otherwise stated)\n* Left ventricular ejection fraction (LVEF) >= 50%\n\n  * Note: Echocardiogram to be performed within 42 days prior to day 1 of protocol therapy\n* Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test. (performed within 14 days prior to Day 1 of protocol therapy unless otherwise stated)\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential* to use an effective method of birth control (non-hormonal) or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 54 Years",
    "exclusion_criteria": "* Leukemia-based therapy with chemotherapy with the exception of:\n\n  * Cytoreduction with steroid or hydroxyurea or a single dose of intrathecal chemotherapy is allowed before initiating the study\n* Strong or moderate CYP3A4 inducers within 14 days prior to day 1 of protocol therapy\n* Subjects who have consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit within 3 days prior to the first dose of study drug\n* Live vaccines\n* Philadelphia chromosome positive (Ph+; t(9;22)), MLL-rearrangement, t(12;21), and t(1;19)\n* T cell ALL\n* Class III/IV cardiovascular disability according to the New York Heart Association Classification. Subjects with controlled, asymptomatic atrial fibrillation can enroll\n* Parenchymal central nervous system (CNS) involvement requiring cranial radiation\n* Participants with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of enrollment\n* History of acute cardiovascular ischemic event, i.e., myocardial infarction or unstable angina within 6 months of enrollment\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Clinically significant uncontrolled illness\n* Uncontrolled active infection\n* Other active malignancy\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
    "miscellaneous_criteria": ""
}